相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide
Alex Shimura Yamashita et al.
NEURO-ONCOLOGY (2019)
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2019)
IDH3α regulates one-carbon metabolism in glioblastoma
Jasmine L. May et al.
SCIENCE ADVANCES (2019)
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence
Sevin Turcan et al.
NATURE GENETICS (2018)
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Tathiane M. Malta et al.
NEURO-ONCOLOGY (2018)
Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
Eytan M. Stein
FUTURE ONCOLOGY (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2 Analysis of a Phase 1/2 Study
Amir T. Fathi et al.
JAMA ONCOLOGY (2018)
Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
Hanumantha Rao Madala et al.
CANCERS (2018)
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
Rui Ma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model
Katharine Yen et al.
CANCER RESEARCH (2018)
Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
Hiroaki Fujiwara et al.
CANCER SCIENCE (2018)
Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.
Bin Fan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma
Ingo K. Mellinghoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Justin M. Watts et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).
Courtney Denton Dinardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
Eytan Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Andrew M. Intlekofer et al.
NATURE (2018)
SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML
Courtney D. DiNardo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
Johanna S. Ungerstedt
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
Ingo Mellinghoff et al.
NEURO-ONCOLOGY (2018)
RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA
Ingo Mellinghoff et al.
NEURO-ONCOLOGY (2018)
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
James J. Harding et al.
CANCER DISCOVERY (2018)
AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies
Katharine Yen et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
Ingo K. Mellinghoff et al.
NEURO-ONCOLOGY (2017)
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
A. Chaturvedi et al.
LEUKEMIA (2017)
Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome
Meera Yogarajah et al.
MAYO CLINIC PROCEEDINGS (2017)
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression
Christopher J. Pirozzi et al.
MOLECULAR CANCER RESEARCH (2017)
EXTH-59. THE IDH1 MUTANT INHIBITOR AG-120 SHOWS STRONG INHIBITION OF 2-HG PRODUCTION IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
Brandon Nicolay et al.
NEURO-ONCOLOGY (2017)
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1
Julian R. Levell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Young Shin Cho et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
Daniel Thomas et al.
CANCER DISCOVERY (2017)
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine Yen et al.
CANCER DISCOVERY (2017)
HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells
Lanlan Tang et al.
ONCOTARGET (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar et al.
CELL REPORTS (2017)
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation
Andrea E. Calvert et al.
CELL REPORTS (2017)
Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2
Aram S. Modrek et al.
CELL REPORTS (2017)
m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells
Qi Cui et al.
CELL REPORTS (2017)
Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma
Maria J. Williams et al.
Frontiers in Oncology (2017)
Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
Rui Lu et al.
FRONTIERS IN ONCOLOGY (2017)
Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q
Jiao Chen et al.
SCIENTIFIC REPORTS (2017)
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit
Johnny Kopinja et al.
SCIENTIFIC REPORTS (2017)
ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.
Maeve Aine Lowery et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
How and when to decide between epigenetic therapy and chemotherapy in patients with AML
Herve Dombret et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Stefan Pusch et al.
ACTA NEUROPATHOLOGICA (2017)
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini et al.
CLINICAL CANCER RESEARCH (2016)
Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
Howard Burris et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Insulator dysfunction and oncogene activation in IDH mutant gliomas
William A. Flavahan et al.
NATURE (2016)
Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics
Gerard Joberty et al.
ACS CHEMICAL BIOLOGY (2016)
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
Satoshi Inoue et al.
CANCER CELL (2016)
Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis
Chiara Bardella et al.
CANCER CELL (2016)
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
Owen Clark et al.
CLINICAL CANCER RESEARCH (2016)
Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
K. C. Birendra et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
John Mascarenhas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Jiao Chen et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Tor-Christian Aase Johannessen et al.
MOLECULAR CANCER RESEARCH (2016)
Mutations of myelodysplastic syndromes (MDS): An update
Bani Bandana Ganguly et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2016)
Phase III randomized, open-label study comparing the efficacy and safety of AG-221 vs conventional care regimens (CCR) in older patients with advanced acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH)-2 mutations in relapse or refractory to multiple prior treatments: the IDHENTIFY trial
Martin S. Tallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
Johanna Mondesir et al.
JOURNAL OF BLOOD MEDICINE (2016)
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
Ashkan Emadi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion
Kensuke Tateishi et al.
CANCER CELL (2015)
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Ujunwa C. Okoye-Okafor et al.
NATURE CHEMICAL BIOLOGY (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Daniel J. Brat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
Luyuan Li et al.
PLOS ONE (2015)
Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries
Patompon Wongtrakoongate
WORLD JOURNAL OF STEM CELLS (2015)
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Andrew Kernytsky et al.
BLOOD (2015)
Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule
Gejing Deng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
IDH2 mutation in gliomas including novel mutation
Jaemoon Koh et al.
NEUROPATHOLOGY (2015)
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
A. P. Im et al.
LEUKEMIA (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer
Eric Brooks et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome
Luciano Cardinale et al.
WORLD JOURNAL OF RADIOLOGY (2014)
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Anuhar Chaturvedi et al.
BLOOD (2013)
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2013)
DNA methyltransferase 1 is essential for initiation of the colon cancers
Rena Morita et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization
Patrick S. Ward et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia
Houry Leblebjian et al.
LEUKEMIA RESEARCH (2013)
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Jiang-Han Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
Alexandra Borodovsky et al.
ONCOTARGET (2013)
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Sevin Turcan et al.
ONCOTARGET (2013)
Acute promyelocytic leukemia, study of predictive factors for Differentiation Syndrome, single center experience
Omyma Elemam et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2013)
Emerging insights into the molecular and cellular basis of glioblastoma
Gavin P. Dunn et al.
GENES & DEVELOPMENT (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG
Phoenix A. Ho et al.
BLOOD (2011)
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Claire L. Green et al.
BLOOD (2011)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Rasheduzzaman Chowdhury et al.
EMBO REPORTS (2011)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
Daniel Krell et al.
PLOS ONE (2011)
The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the Literature
Pau Montesinos et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2011)
The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
Fonnet E. Bleeker et al.
ACTA NEUROPATHOLOGICA (2010)
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status
Claire L. Green et al.
BLOOD (2010)
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2010)
Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia
Maaike Luesink et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Molecular mechanisms of off-on switch of activities of human IDH1 by tumor-associated mutation R132H
Bei Yang et al.
CELL RESEARCH (2010)
Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
Katharina Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia
Ramzi Jeddi et al.
LEUKEMIA RESEARCH (2010)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors
Pau Montesinos et al.
BLOOD (2009)
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Hai Yan et al.
CANCER RESEARCH (2009)
IDH1 Mutations at Residue p.R132 (IDH1R132) Occur Frequently in High-Grade Gliomas But Not in Other Solid Tumors
Fonnet E. Bleeker et al.
HUMAN MUTATION (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Arsenic trioxide: safety issues and their management
Wing-Yan Au et al.
ACTA PHARMACOLOGICA SINICA (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Structural studies on 2-oxoglutarate oxygenases and related double-stranded β-helix fold proteins
Ian J. Clifton et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2006)
分享论文
